Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jun;10(6):2715-2718.
doi: 10.21037/tau-21-453.

Expectant management in genitourinary malignancies (prostate, bladder, kidney)

Mieke Van Hemelrijck  1 , Netty Kinsella  1   2
Affiliations
Editorial

Expectant management in genitourinary malignancies (prostate, bladder, kidney)

Mieke Van Hemelrijck et al. Transl Androl Urol. 2021 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-21-453). The series “Expectant Management in Genitourinary Malignancies (Prostate, Bladder, Kidney)” was commissioned by the editorial office without any funding or sponsorship. Drs. Van Hemelrijck and Kinsella served as the unpaid Guest Editors of the series. Dr. Kinsella reports no honorariums or consulting fees received in the last 12 months, but Astellas, Janssen and Koelis for lectures and conference preparation only. The authors have no other conflicts of interest to declare.

Figures

None
Mieke Van Hemelrijck
None
Netty Kinsella
See this image and copyright information in PMC

References

    1. Shill DK, Roobol MJ, Ehdaie B, et al. Active surveillance for prostate cancer. Transl Androl Urol 2021. doi: 10.21037/tau-20-1370 - DOI - PMC - PubMed
    1. Crump RT, Remmers S, Van Hemelrijck M, et al. Using the Movember Foundation’s GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function—a retrospective study in low-risk prostate cancer patients. Transl Androl Urol 2021. doi: 10.21037/tau-20-1255 - DOI - PMC - PubMed
    1. Beckmann K, Cahill D, Brown C, et al. Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer. Transl Androl Urol 2021. doi: 10.21037/tau-20-1254 - DOI - PMC - PubMed
    1. Roobol MJ. Active surveillance for prostate cancer—will the discoveries of the last 5 years change the future? Transl Androl Urol 2020. doi: 10.21037/tau-20-1321 - DOI - PMC - PubMed
    1. Russell B, Kotecha P, Thurairaja R, et al. Endoscopic surveillance for bladder cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 2021. doi: 10.21037/tau-20-1363 - DOI - PMC - PubMed

Publication types